



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/313,628	05/18/1999	GARY D. HODGEN	P/1890-201(D	4153
7590	02/18/2005		EXAMINER	
Edward A Meilman			MITCHELL, GREGORY W	
DICKSTEIN SHAPIRO MORIN & OSHINSKY				
1177 Avenue of the Americas			ART UNIT	PAPER NUMBER
41st Floor			1617	
New York, NY 10036-2714				
DATE MAILED: 02/18/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

**Advisory Action
Before the Filing of an Appeal Brief**

Application No.

09/313,628

Applicant(s)

HODGEN, GARY D.

Examiner

Gregory W Mitchell

Art Unit

1617

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 03 January 2005 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. The reply was filed after a final rejection, but prior to filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

a) The period for reply expires _____ months from the mailing date of the final rejection.

b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. The reply was filed after the date of filing a Notice of Appeal, but prior to the date of filing an appeal brief. The Notice of Appeal was filed on 03 January 2005. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because

(a) They raise new issues that would require further consideration and/or search (see NOTE below);

(b) They raise the issue of new matter (see NOTE below);

(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or

(d) They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: _____. (See 37 CFR 1.116 and 41.33(a)).

4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).

5. Applicant's reply has overcome the following rejection(s): See Continuing Sheet.

6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: _____.

Claim(s) objected to: _____.

Claim(s) rejected: 21-33.

Claim(s) withdrawn from consideration: 34-43.

AFFIDAVIT OR OTHER EVIDENCE

8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).


10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuing Sheet.

12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s).

13. Other: _____.


SREENI PADMANABHAN
SUPERVISORY PATENT EXAMINER

Continuation of 5:

Applicant's arguments regarding the 35 USC 112 rejections of the Office Action dated July 01, 2004 are persuasive. Accordingly, the 35 USC 112 rejections of claims 21-33 are hereby withdrawn.

Continuation of 11:

The rejection of claims 21-33 under 35 USC 103 are maintained.

Applicant argues that the 35 USC 103 rejection of the Office Action dated July 01, 2004 "presupposes that a composition is being claimed and that it was known to use progestogenic agent to effect the bleeding side effect of the SERM[,] but a method is being claimed and there is nothing in the record to suggest that [] progestogenic agent[s are] known to effect the bleeding side effect of the SERM in any way." This argument is not persuasive. First, it would have been obvious to one of ordinary skill in the art to combine two compositions known to be individually useful for the same purpose to provide a third composition for the very same purpose (it would have also been obvious to administer said third composition for said purpose). Second, the instant claims are drawn to a method of achieving contraception, not a method of ameliorating the bleeding side effect of SERMS. Third, it is known in the art, as taught by the Merck Manual of Medical Information, that bleeding is a normal side effect of oral contraceptives. Accordingly, it would have been obvious to one of ordinary skill in the art to administer a composition comprising both SERMS and inhibitors of progestogenic activity for the purpose of achieving contraception and it would have been within the routine skill of the art to formulate a dosage composition wherein the bleeding side effect associated therewith would be minimized.

It is noted that claims 34-43 remain withdrawn from consideration because said claims are drawn to a method of ameliorating uterine bleeding whereas the instant invention is drawn to a method of providing contraception.